CS Paper Radar

Conserved Immune Topology Improves Pathology Foundation Model Generalization for Cross-Cancer MSI-H Prediction

Dasari Naga Raju

cs.CV ·submitted 2026-09-04 14:17 UTC · v1
published

Abstract

Pathology foundation models integrated with multiple instance learning achieve competitive accuracy within single-cancer cohorts, yet cross-cancer generalization remains unresolved due to organ-specific histological and architectural differences. In this paper, we propose Conserved Immune Topology (CIT), a lightweight spatial representation for cross-cancer MSI-H prediction that augments foundation-model embeddings with biologically motivated immune descriptors. CIT uses unsupervised clustering to identify immune-associated tiles, then encodes tertiary lymphoid structures, peritumoral immune reactions, multi-scale tumor-infiltrating lymphocyte density, and immune-tumor mixing from frozen foundation-model embeddings and tile coordinates without requiring annotations or target-domain data. The proposed method was evaluated under cross-site and cross-cancer settings using CPTAC-COAD and TCGA-STAD cohorts, which introduce scanner variability, distribution shifts, and organ-specific architectural variations. Zero-shot cross-cancer transfer with CIT increased TransMIL AUC from 0.6627 to 0.7161, an absolute gain of 0.0534 (p=0.003), with consistent improvements across all three MIL aggregators. These results suggest that spatial immune topology provides potentially an organ-invariant representation for MSI-H prediction, supporting cross-cancer generalization of pathology foundation models.

Comment
Accepted at the ECCV 2026 Workshop on Medical Foundation Models and Benchmarks (MedFM-Bench). 15 pages, 2 figures

Closest papers

Nearest neighbours by meaning across the whole index.

TIRA: Tumor Immune Representation Adaptation for Zero-Shot Cross-Cancer MSI and TMB Prediction

cs.CV ·2026-10-07 ·Dasari Naga Raju
similarity 0.83
Abstract

Microsatellite instability-high (MSI-H) and high tumor mutational burden (TMB-H) are clinically relevant biomarkers, yet their histopathological prediction remains challenging when models are transferred across morphologically distinct cancer types. Immune-associated spatial patterns can persist across cancers despite these morphological differences, but foundation-model-based predictors trained on a single cancer do not explicitly use this information, limiting cross-cancer generalization. To address this limitation, we propose TIRA (Tumor Immune Representation Adaptation), a target-free framework that refines frozen foundation-model representations using spatial immune topology, without requiring target-domain data during model development or test-time adaptation. TIRA uses a topology-supervised biology representation to condition tile-level attention while pooling only morphological features for joint MSI and TMB prediction. We train TIRA on TCGA-COAD+READ and evaluate it zero-shot on CPTAC-COAD, TCGA-STAD, TCGA-UCEC, and CPTAC-UCEC, covering cross-site, cross-cancer, and combined cross-cancer-site distribution shifts under UNI2, CONCH, and Virchow2. With UNI2, TIRA improved zero-shot AUROC on TCGA-STAD from 0.633 to 0.766 for MSI and from 0.651 to 0.772 for TMB. Source-derived spatial immune topology improved the cross-cancer robustness of frozen pathology foundation-model representations.

0.04

Multimodal LLMs Outperform Pathology Foundation Models in Cross-Domain Histological Similarity

cs.CV cs.AIcs.CLcs.LG ·2026-09-26 ·Yishu Zhang, Yun Li, Daiwei Zhang
publishedbenchmark similarity 0.63
Abstract · To appear in NeurIPS 2026 (https://neurips.cc/virtual/2026/poster/152201)

State-of-the-art pathology foundation models, trained on millions of histology tiles, can fail to preserve tissue similarity when comparisons cross slide or institution boundaries. We show that general-purpose multimodal LLMs, without being trained as pathology foundation models, consistently outperform these specialized models in cross-domain histological similarity judgments. Using a relative similarity framework that we release as the MOSAIC (Model Similarity Assessment across Institutions and Cohorts) benchmark, we evaluate 17 models across 6 datasets and find that pathology encoders often rank same-institution, different-disease tiles as more similar than same-disease, different-institution tiles, a clinically dangerous failure mode invisible to standard within-domain evaluations. LLMs appear less susceptible to this failure, likely because they perform semantic visual comparison of morphology and tissue architecture rather than relying on shortcut features tied to acquisition context. Scaling training data does not resolve the problem for pathology encoders, implicating the learning objective rather than data coverage. Our results expose a fundamental robustness gap in current pathology foundation models and establish multimodal LLMs as a viable alternative for cross-institutional retrieval, dataset harmonization, and multi-site quality control. Code and data will be released upon acceptance.

0.35

HEmIF-Bench: Benchmarking H&E-to-mIF Models BeyondVirtual-StainFidelity

cs.CV ·2026-11-15 ·Fuxian Zhao, Hyokeun Park
benchmark similarity 0.63
Abstract · 11 pages, 3 figures, 2 tables

Hematoxylin and eosin (H&E)-to-multiplex immunofluorescence (mIF) generators predict spatial protein expression from routine histology, yet pixel-level marker reconstruction does not establish downstream utility. We present HEmIF-Bench, evaluating five frozen generators across eight datasets spanning molecular, cellular, tissue, and patient scales. HEmIF-Bench decouples internal encoder features from generated outputs, benchmarking both against the pathology foundation reference UNI2. Mirroring the clinical workflow where pathologists rely on mIF to define cell phenotypes, delineate tertiary lymphoid structures (TLSs) and germinal centers (GCs), and stratify patient risk, we evaluate external CD3 recovery, single-cell classification, dense nuclear segmentation, TLS/GC segmentation, and patient survival prediction. Across the benchmark, foundation-model-based MIPHEI-ViT leads among the generators, while non-foundation models show task-specific strengths. Comparing the two routes reveals that internal encoder features generally outperform generated outputs, and larger output marker panels do not guarantee stronger downstream utility across datasets. Moreover, neither internal encoder features nor generated outputs consistently surpass frozen UNI2. These findings show that pixel-level stain fidelity does not equate to downstream utility, and that generators trained at current paired-data scales have yet to surpass large-scale pure-H&E foundation models. With the expansion of paired translation cohorts and the advancement of foundation-based generative architectures, HEmIF-Bench establishes a definitive benchmark for tracking when H&E-to-mIF generation crosses the threshold to deliver genuine value beyond routine histology for tumor microenvironment analysis and precision oncology.

0.13

MoSPR: Histology-to-Gene Expression Prediction with Morpho-Spatial Macrostates and Low-Rank Molecular Programs

cs.AI cs.CVcs.LG ·2026-09-28 ·Dongmyung Shin, Geongyu Lee, Yesung Cho, Park Jong Bae
code/data similarity 0.62
Abstract

Predicting molecular profiles from histopathology remains challenging because whole-slide images contain spatially organized, heterogeneous tissue patterns, while gene expression comprises thousands of correlated targets. We introduce MoSPR (Morpho-Spatial Program Regression), a linear framework that couples an adjacency-informed histology representation with a low-rank molecular basis. MoSPR clusters frozen patch embeddings into morphology microstates, aggregates their spatial adjacencies across the training cohort, and groups microstates with similar adjacency patterns into shared macrostates. Each slide is then represented by global morphology and macrostate-specific deviations, which are linearly mapped to coefficients of a training-derived low-rank gene-expression basis. Across three cancer cohorts from The Cancer Genome Atlas, MoSPR achieves the highest mean gene-expression prediction scores among all evaluated methods. Without pathway-level supervision, pathway scores derived from its predicted expression profiles rank first in eight of nine comparisons across three pathway collections. Ablation studies on the breast cancer cohort show complementary gains from adjacency-derived macrostate representation and low-rank molecular prediction. Moreover, with half of the training data on this cohort, MoSPR exceeds the full-data gene-prediction score of the strongest competing baseline. Finally, its linear formulation enables exact decomposition of each predicted expression profile into global and macrostate-specific molecular contributions, providing an interpretable link between spatially coherent macrostate regions and their associated molecular programs. Our code is available at https://github.com/Radisen-Panthera/MoSPR.

0.20

MOSAIC: Towards a Universal Latent Space for Computational Pathology Foundation Models

cs.CV cs.AI ·2026-10-19 ·Dibaloke Chanda, Praveen Madiraju
publishedcode/data similarity 0.62
Abstract · Accepted at WACV 2027

Pathology foundation models (PFMs) differ substantially in architecture, pretraining objective, training data and representation dimensionality, yet it remains unclear whether they learn fundamentally different feature spaces or alternative coordinate systems of a shared underlying representation. We present MOSAIC, a systematic study of latent-space similarity, alignment and interoperability across $12$ patch-level and $6$ slide-level PFMs. We first quantify representational agreement using complementary similarity measures and analyze how architecture, pretraining objective, network depth and magnification influence latent geometry. We then evaluate multiple alignment strategies for mapping independently learned representations into a common latent space. The resulting representations are evaluated through cross-model agreement, retrieval, geometry preservation, and downstream multiple-instance learning across molecular and morphological prediction tasks. MOSAIC provides a unified framework for studying whether heterogeneous PFMs can move beyond representational similarity toward a shared and functionally transferable pathology representation space. Our code, benchmarks and additional results are available at https://researchsubmissions66.github.io/MOSAIC/.

0.42

Cross-Modal Contrastive Learning for the Retrieval of Immunotherapy-Associated Molecular Signatures from Histopathology

cs.LG cs.AIcs.IR ·2026-10-04 ·Sigrid Vila-Bagaria, Mar Teixidó, Miquel Piñol, Felip Vilardell, Robert Montal +1 more
published similarity 0.62
Abstract · Accepted to MICCAI 2026 CaPTion Workshop

Gastric Adenocarcinoma is a leading cause of cancer mortality. Although "Inflamed/Non-Inflamed" subtypes have been proposed to predict immunotherapy response, their identification relies on a costly 10-gene RNA signature. We propose a Cross-modal Contrastive Multiple Instance Learning (CCMIL) framework for cross-modal retrieval, imputing these molecular signatures directly from standard Hematoxylin & Eosin (H&E) slides. By leveraging a supervised contrastive objective, CCMIL aligns visual morphological patterns with molecular phenotypes into a shared latent space. This establishes an interpretable search-by-case retrieval engine, enabling pathologists to query a whole slide image to surface transcriptomically coherent neighbors and approximate RNA signatures without genomic sequencing at inference. Our results demonstrate that this retrieval-first approach captures the continuous phenotypic spectrum of tumor inflammation and yields clinically interpretable attention heatmaps. Furthermore, the learned representation also supports competitive downstream classification, providing a practical molecular pre-screening strategy.

0.26

AI-based characterization of lymphoid structures and the tumor microenvironment reveals lower mature tertiary lymphoid structures, lymph-node follicles, and plasma cells after neoadjuvant therapy in lung squamous cell carcinoma

cs.CV q-bio.QM ·2026-11-09 ·Arne Schmidt, Justin Nieder, Cornelius Boehm, Julika Ribbat-Idel, Marius Teodorescu +22 more
similarity 0.61
Abstract

Mature, germinal centre-bearing tertiary lymphoid structures (TLS) and mature lymph node follicles (secondary lymphoid structures, SLS) sustain the plasma cell response that shapes outcome and immunotherapy benefit in lung cancer. How this loco-regional axis differs between neoadjuvant-treated and therapy-naive tumors is poorly defined. We analyzed H&E whole-slide images of resected tumors and paired proximal and distal lymph nodes from matched neoadjuvant-treated (neoLUSC, n=20) and therapy-naive (naivLUSC, n=20) lung squamous cell carcinoma (LUSC) patients. Aignostics Atlas H&E Tissue Analysis (HETA) models quantified cell densities per tissue compartment and cell-cell co-localization; a dedicated deep-learning model validated against pathologist annotations detected TLS and SLS and graded their maturity. Prognostic value was tested in an independent cohort (n=458; 46 treated). In neoLUSC tumors, stromal plasma cell density was 72% (p=0.004) and stromal lymphocyte density 48% (p=0.015) lower than in naivLUSC; macrophages and granulocytes did not differ significantly. Total and immature TLS did not differ, whereas mature TLS in the tumor (p=0.034) and mature SLS in the tumor-distal lymph node (p=0.003) were lower in neoLUSC patients. Peri-TLS plasma cell density correlated with tumor lymphocyte density in naivLUSC (rho=0.54, p=0.017) but not in neoLUSC tumors (rho=0.07). In the validation cohort, stromal plasma cell density (HR 0.69, p=0.011) and lymphocyte-plasma cell co-localization (HR 0.66, p=0.004) were associated with longer survival, and neoadjuvant status with shorter survival (HR 1.50, p=0.026). Neoadjuvant therapy is thus associated with fewer mature lymphoid structures and weaker coupling of the humoral compartment to the tumor rather than uniformly lower immune readouts. The stromal plasma cell/co-localization axis is a candidate prognostic biomarker.

0.31

CellPlex: Benchmarking Single-Cell Spatial Proteomics Prediction from H&E

cs.CV ·2026-11-02 ·Zijun Gao, Yijiang Chen, Xiangde Luo, Pheng-Ann Heng
benchmark similarity 0.61
Abstract

Spatial proteomics measures tens of proteins in every cell of a tissue section, but its cost confines it to small research cohorts, whereas hematoxylin and eosin (H\&E) slides exist for nearly every patient. Inferring single-cell spatial proteomics from H\&E would bring its analyses to routine pathology, and a growing number of virtual staining models pursue this goal. Each is evaluated on its own cohort, panel and pixel-level metric, and released models transfer poorly to new cohorts, leaving open which approach to build on and which proteins H\&E can reveal. We introduce CellPlex, a benchmark that poses the task at the level of the cell: seven cohorts with same-section H\&E and multiplexed immunofluorescence, from colorectal and breast cancer to lymph-node metastases, bone marrow and glioma, with 717 samples, 44.8 million cells and 149 proteins, processed by one pipeline into per-cell targets. Pathology foundation models (PFMs) are adapted with one cell-level protocol, specialist models are fine-tuned under a matched budget, and all are scored on the same cells. Adapted PFMs are the most accurate models on every cohort, ahead of the specialists even after fine-tuning, but keep less than half of their accuracy on cohorts they were not trained on. Which proteins can be predicted depends on the tissue, not on how many cells were measured for them. By fixing the cells, targets and splits on which predictions are judged, CellPlex sets a common standard for inferring costly molecular measurements from routine H\&E and shows how far H\&E can stand in for spatial proteomics. We will release the data, splits, evaluation code and baselines as a testbed for developing and comparing future pathology foundation models and virtual staining methods.

0.21